Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|September 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Epilepsy and Its Medical Management
- Volume 4
- Issue 9 Suppl
Selected Abstracts
Advertisement
Articles in this issue
about 28 years ago
Participating Facultyabout 28 years ago
Medical Management of Epilepsy: Issues and Implicationsabout 28 years ago
Demographics and Cost of Epilepsyabout 28 years ago
Anticonvulsants: Choices and Costsabout 28 years ago
Care of Children With Epilepsyabout 28 years ago
Referral Centers and Specialized Careabout 28 years ago
Vagus Nerve Stimulationabout 28 years ago
Determining Costs and Cost-Effectiveness of Epilepsyabout 28 years ago
CME Quizabout 28 years ago
BibliographyAdvertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
3
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5